{"name":"AlloVir","slug":"allovir","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Multivirus-specific T cells Dose Level 1","genericName":"Multivirus-specific T cells Dose Level 1","slug":"multivirus-specific-t-cells-dose-level-1","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Multivirus-specific T cells Dose Level 1","genericName":"Multivirus-specific T cells Dose Level 1","slug":"multivirus-specific-t-cells-dose-level-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVXpCV25oMmg5aTBBVVZ2cGd1OG9aLUR0aTJJQ2ZHeXQ2TWdHU0gweVlLZ2dXbmVhLXlCaG55X1d2M18yT1J2bk5QbEtXY0JoYWZtbmVrWV96MHVBcW4yOWNaMDhVbWtDTGh1Vkc1UG05em1PaGhVYVRpcFZmbUhCaXBYVU5NcGNXbGljY29fSVUwTzhabmUzSDg3OXk1RS1zc0drUFBPSXJ5WFVyVmZ4RXRVSG92Tk11cFJoVG5sdmFxZTNJdk4wNmQ1VTBGSnNUZ09fbXN4NGpRZEgxYUJzZURPclZ3WnFjNlhaclEwWXBCSGZqdC1QMzNaMXU?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxORzBPX0NON1JQVEU5SGxSY1dQcHBucFZ4b3FvQXVyZm8zQ2RzRTlBbFdxQThVWmE1QjVqVnQ1WTBpVjhVSFMxMnBsNi13OGM1aFNRWDQxR2xjRG5SdEpmcVZrdGg5XzlGX0hEMzYyRHN3R0FDSlJ3VzVpUEpWU2YxNTI2S1lhQQ?oc=5","date":"2025-03-22","type":"deal","source":"Ophthalmology Times","summary":"Kalaris and AlloVir Inc. complete merger - Ophthalmology Times","headline":"Kalaris and AlloVir Inc. complete merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxORWJGcU50S3lKQXNxX2luZ3RVNG94djdsQ1JJSjI4SjRwdG5hYmxtMUhRYS1abmlycmdUZUVkYmdfejVlcHZKV0dhRV8tSXpYOWRabjE0akJacVdBZ1UzVGdod09fWlo4cWRmR2FEYS1oWkl3TkN6TTQybUVIODVJUjdaRFdwRGl4dFRIVVhUcjBkeDZnUjI1ajM3cExkSVNVWl9xMF9n?oc=5","date":"2025-01-09","type":"pipeline","source":"citybiz","summary":"Orna Therapeutics Appoints Vikas Sinha to its Board of Directors - citybiz","headline":"Orna Therapeutics Appoints Vikas Sinha to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ2lBcENGZEN3aXNEbi0tVS0xc2dzd3BVMEdscEd5ZjhZVExtMlNNM0JVTlprZ0pBUERPaWUtdzN1ZkFqZnkyLW9YV3RuaUR5MTFldFV2cUxIekh0M3YzZHRCX2RJZTlCd3JtcVRhWGV3VVV3X2FxaE16R0IzMFJqaV9UT0xFRU1TODJXbmQtcW0wZENWZ0pfQQ?oc=5","date":"2024-11-11","type":"pipeline","source":"Healio","summary":"AlloVir to merge with Kalaris Therapeutics - Healio","headline":"AlloVir to merge with Kalaris Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQYzJzelNVSXE0TnFMN1ptYUNBM1lFTWNUeGlSQ1AycVAtWXZ5eXpfXzdYdlZNNHBJTFhoRW9kQVF2aEJzYnZnQXdocmdMY0hfWkk0WWk1YjR0cmE1TWYzRk5uZDlnSHJadXptbm43S0JFZWZScDlGTU84QTNCNlY3ZDZxeGVPNThNNlN2Q3UwLWdsaXgzZVNXaUUxTTFwYjloT0tDN3Zn?oc=5","date":"2024-11-08","type":"pipeline","source":"fiercebiotech.com","summary":"Struggling AlloVir finds new identity by merging into eye disease biotech - fiercebiotech.com","headline":"Struggling AlloVir finds new identity by merging into eye disease biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQY2RSNno3RlNFSmxib0JOTldNZmFyYkRSNkMzT0ZjYmFWRGxMdnRkV0VfdE9xZWRuOWdMaklQRktJSWxVemZEODZyblMxUDhLckQyNm9VS1oyM1FkR0pncHJuZmRIbmVkbUlGZUpya3l3V3pXTjN3RG5aU3g4N0Jvc3o1UEJxWnlMYWUxVmlSdmg1aEk?oc=5","date":"2024-11-08","type":"deal","source":"BioPharma Dive","summary":"Kalaris to go public via reverse merger with AlloVir - BioPharma Dive","headline":"Kalaris to go public via reverse merger with AlloVir","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNWkhZRnFEQXRNNnBkU0xkSWJRS3ZHOWZFZXNubU9pZ2FCVUJnUkg2X2VtSTg3VVJRSk1mNXNsZ09seVAzNHdMaWUtT1RaaC16S2U1WDNUY1hfZnJKTkZ2U21KbzV2VEZqTUNnUnZOLWRRNUY1MlppemVaT1JUVEhMTGNadTZEc0tOSDhLMkN6SW44N09rQzdnQTNyQQ?oc=5","date":"2024-11-08","type":"deal","source":"The Pharma Letter","summary":"AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter","headline":"AlloVir announces merger with Kalaris Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPdmVtWXVSTS1zR3BtVTJ4SVRwZlp1SUlKWHV6emJRUWtfa0IyWEtsS0lCS25VMUFMck9JMUNldXhqYjBwaE5KOWh3SEpMZHE3LWZiVlVaVWpZSEZjWHd1ajlnc1Y0eUMwTjV2YTA2Z3R4RGt0dGZYVnl1Ylp5YWJVeV9JOTB2ZWdnZjhPM1U3T09hQ1FGMFl1aUdFZmgzUDJoMng0a1FWWjRFSEFIckZIQWhTNVRvRWk3V09kdG10WnBKYm1LR1hCbTJoR2Z2eE5NMG1TLU9tZWpZWlBWXzZrZVo4ckwzS3g5MVow?oc=5","date":"2024-07-04","type":"trial","source":"prnewswire.com","summary":"BK Virus Infection Market to Witness Surge in Growth During the Study Period (2020-2034) | DelveInsight - prnewswire.com","headline":"BK Virus Infection Market to Witness Surge in Growth During the Study Period (2020-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOOG9DSV8zSWZSSFB0ZlhwNEJadXE4SEhHbUN4eFhWbTJEYWdqSnE5VjlPdGx2emVkZTltRl9jSHEyVEE2aWgzYUNra2ZfeWREdVZLcDlOTURxU1dUaFdUaHY1bHBaNVJ0Wmp0SGdEN0xPVzJpbTBNc1pOZjNybGVPck1HQk5VU0dlZGFaRWYwWDZ6ajY4b3RNem13?oc=5","date":"2024-01-05","type":"trial","source":"fiercebiotech.com","summary":"Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce - fiercebiotech.com","headline":"Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5aYTBrSlpMU0hCcVhXS0wwemNGSzF0V2R1bTkzVjRKSGNxM1ZtV2xmRHNzSlhMQm82MWJUN1FUekdkdHJHSWcwYUw1c1M1R2QtNEhJakFyQkgtLXZ4M2NrR04yaDhfT1l0aklhQTlHSU9rYWF6RGM1cXdJeGZwdw?oc=5","date":"2023-09-05","type":"deal","source":"BioSpace","summary":"Why Biopharma Companies Buy Stock in One Another - BioSpace","headline":"Why Biopharma Companies Buy Stock in One Another","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNTWdVOWRXTWVUSlYwQjNSbzQ3RjFzUFJGMk9kWkZHaEhsMUREdEdtWmZBWHl5UDM0U2dwUmczUjFkTkM4LWNXMFhzck54M2FTYWlIQXFNZjh0dlhOQUdLY2JnTFJ3U3NQN3JGc1hBWGxJbjl0NV9kVWZrclRIWTR2dHVR?oc=5","date":"2023-07-12","type":"pipeline","source":"Barron's","summary":"Gilead Just Bought $30 Million More of 2 Biotech Stocks - Barron's","headline":"Gilead Just Bought $30 Million More of 2 Biotech Stocks - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQWll1SUFEVUsxVDFZam16VTVzRGxqMEdtVFVLVFJiV1N4aFBGZzVMWG4ycHBvd2lDc0FZZ2RvRzlnYVV1WWlKOG8tSmo0Qm1PeW5qUWR3SkJGWjZJYzFxS3BjZ20ybEV0ZVYyNWpiTkdBU0txVTFDckNkMVBEOU9JblVLWVhZUklpTGkzaEZCZEwxRWJtYXFrdTc5X0JZYnpYSHY5XzBEbE5udUQzZnZfYVEtSQ?oc=5","date":"2021-09-27","type":"pipeline","source":"Bloomberg.com","summary":"Brothers Who Made Billions on Pharma Firm Boost Health Bets - Bloomberg.com","headline":"Brothers Who Made Billions on Pharma Firm Boost Health Bets","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}